Cempra (CEMP +3.6%) rises after getting a five year contract worth up to $58M to develop its...


Cempra (CEMP +3.6%) rises after getting a five year contract worth up to $58M to develop its lead product candidate solithromycin (an antibiotic under development for the treatment of community-acquired bacterial pneumonia) for use in pediatrics and as a defense against bioterrorism. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs